TABLE 1.
THERAPEUTIC APPLICATIONS OF HO-1 END-PRODUCTS
| Molecule | Injury/Disease Model | Protection Phenotype | References |
|---|---|---|---|
| Carbon monoxide (gas) | Systemic endotoxemia (mice) | Decreased proinflammatory cytokine production | 25 |
| Hyperoxia-induced acute lung injury (mice) | Decreased proinflammatory cytokine production, increased survival | 99, 106 | |
| Lung ischemia/reperfusion injury (mice) | Reduced apoptosis | 107 | |
| Ventilator-induced lung injury (rats and mice) | Decreased proinflammatory cytokine production | 4, 94, 108 | |
| Vascular injury (rats and mice) | Reduced inflammation, inhibition of vascular smooth muscle proliferation | 26 | |
| Pulmonary hypertension (rat) | Inhibition of smooth muscle proliferation, increased smooth muscle apoptosis | 109 | |
| Cytokine-induced liver injury (mice) | Organ preservation, reduced apoptosis | 120 | |
| Organ transplantation (lung, heart, liver, kidney, small intestinal) (rat) | Decreased inflammation, apoptosis, reduced graft rejection | 12, 110–114, 121 | |
| Systemic endotoxemia (pigs) | Improved organ function, decreased proinflammatory cytokine production | 122 | |
| Carbon monoxide (CORM) | Systemic endotoxemia (mice) | Decreased inflammation | 123 |
| Organ transplantation | Improved organ function | 124 | |
| Biliverdin/Bilirubin | Vascular Injury (rats) | Inhibition of smooth muscle proliferation | 115 |
| Transplantation (rats) | Decreased inflammation, apoptosis, reduced graft rejection | 113, 27–29 |